{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:48:16Z","timestamp":1754488096192,"version":"3.41.2"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold>Transcatheter closure is an important treatment for patent ductus arteriosus (PDA) complicated with moderate and severe pulmonary arterial hypertension (PAH). This report presents our experience with transcatheter closure of PDA complicated with moderate and severe PAH.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold>The 49 cases of PDA complicated with moderate and severe PAH were collected in the Second Affiliated Hospital and Yuying Children's Hospital from January 2014 to December 2019 with transcatheter closure of PDA and follow-up. All patients were invited for transthoracic echocardiography, electrocardiogram, and thoracic radiography check-up.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold>Device implantation was successful in 48 of 49 patients (98.0%). Among them, 30 cases were in the PAH after defect correction (CD) group, and 19 examples were in the Non-PAH after defect correction (NCD) group. Pulmonary systolic pressure, left atrial diameter, and left ventricular end-diastolic diameter immediately after interventional therapy and 6 months later were lower than the pre-operative levels (<jats:italic>p<\/jats:italic>&amp;lt; 0.05). The incidence of the immediate residual shunt (RS) in this study was 34.9%, most of which were minimal amount shunt. RS disappeared in all patients within 1 year of therapy. Four patients had thrombocytopenia and one patient had left pulmonary artery stenosis. No other serious adverse event occurred during the follow-up period. The pressure gradient tricuspid valve regurgitation (PGTI) and the right heart catheterization (RHC) consistency points were 93.75% (15\/16) and were within the 95% consistency limit by the Bland-Altman method. The Logistic regression analysis concluded that the pre-operative Pp\/Ps and the narrowest diameter of PDA are risk factors for post-operative PAH (<jats:italic>p<\/jats:italic>&amp;lt; 0.05). The cut-off point of the pre-operative Pp\/Ps and the narrowest diameter of PDA were calculated to be 0.595 and 4.75 mm, respectively.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold>Interventional occlusion in children with PDA complicated with moderate and severe PAH is safe, effective, and has few complications. Targeted drug therapy has a good clinical effect. The narrowest diameter of PDA and the pre-operative Pp\/Ps may be one of the risk factors of residual PAH after interventional therapy.<\/jats:p>","DOI":"10.3389\/fcvm.2021.693414","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T05:43:27Z","timestamp":1636609407000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Post-interventional Evaluation and Follow-Up in Children With Patent Ductus Arteriosus Complicated With Moderate to Severe Pulmonary Arterial Hypertension: A Retrospective Study"],"prefix":"10.3389","volume":"8","author":[{"given":"Xing","family":"Rong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaofang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiongjun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongzhou","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2174\/157339631202160506002215","article-title":"Pathophysiology of patent ductus arteriosus in the preterm infant","volume":"12","author":"Vettukattil","year":"2016","journal-title":"Curr Pediatr Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/1522-726X(200009)51:1","article-title":"Closure of the patent ductus arteriosus with the amplatzer PDA device: immediate results of the international clinical trial","volume":"51","author":"Faella","year":"2000","journal-title":"Catheter Cardiovasc Interv."},{"key":"B3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0735-1097(00)01094-9","article-title":"The Amplatzer duct occluder: experience in 209 patients","volume":"37","author":"Bilkis","year":"2001","journal-title":"J Am Coll Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.pedneo.2019.10.002","article-title":"Therapeutic strategy of patent ductus arteriosus in extremely preterm infants","volume":"61","author":"Su","year":"2020","journal-title":"Pediatr Neonatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1183\/13993003.01032-2015","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"46","author":"Galie","year":"2015","journal-title":"Eur Respir J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/CIRCINTERVENTIONS.113.001135","article-title":"Trial occlusion to assess the risk of persistent pulmonary arterial hypertension after closure of a large patent ductus arteriosus in adolescents and adults with elevated pulmonary artery pressure","volume":"7","author":"Zhang","year":"2014","journal-title":"Circ Cardiovasc Interv."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1053\/euhj.2001.2605","article-title":"Association for European C. Transcatheter coil occlusion of the arterial duct; results of the European Registry","volume":"22","author":"Magee","year":"2001","journal-title":"Eur Heart J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jacc.2004.03.074","article-title":"Multicenter USA Amplatzer patent ductus arteriosus occlusion device trial: initial and one-year results","volume":"44","author":"Pass","year":"2004","journal-title":"J Am Coll Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1017\/S1047951114000183","article-title":"Closure of large patent ductus arteriosus using the Amplatzer Septal Occluder","volume":"25","author":"Garcia-Montes","year":"2015","journal-title":"Cardiol Young."},{"key":"B10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3760\/cma.j.issn.0253-3758.2013.03.012","article-title":"Retrospective analysis of patients with thrombocytopenia after patent ductus arteriosus interventional occlusion","volume":"41","author":"Liao","year":"2013","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1801887","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur Respir J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ccm.2015.02.007","article-title":"Pulmonary vascular diseases","volume":"36","author":"Cummings","year":"2015","journal-title":"Clin Chest Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S0022-5223(19)36976-4","article-title":"The clinical value and risks of lung biopsy in children with congenital heart disease","volume":"99","author":"Wilson","year":"1990","journal-title":"J Thorac Cardiovasc Surg."},{"key":"B14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/1010-7940(91)90209-3","article-title":"Is lung biopsy useful for surgical decision making in congenital heart disease?","volume":"5","author":"Frescura","year":"1991","journal-title":"Eur J Cardiothorac Surg"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1001\/jama.2014.2632","article-title":"Comparison of application of the ACC\/AHA guidelines, adult treatment panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort","volume":"311","author":"Kavousi","year":"2014","journal-title":"JAMA."},{"key":"B16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1517\/14796678.1.3.299","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"1","author":"Provencher","year":"2005","journal-title":"Future Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ijcard.2013.12.179","article-title":"Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients","volume":"172","author":"Simonneau","year":"2014","journal-title":"Int J Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1161\/01.CIR.76.5.1037","article-title":"Isolated atrial septal defect with pulmonary vascular obstructive disease\u2013long-term follow-up and prediction of outcome after surgical correction","volume":"76","author":"Steele","year":"1987","journal-title":"Circulation."},{"key":"B19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/01.cir.0000032875.55215.cb","article-title":"Inhaled nitric oxide as a preoperative test (INOP Test I): the INOP test study group","volume":"106","author":"Balzer","year":"2002","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1751-7133.2010.00202.x","article-title":"Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension","volume":"17","author":"Farber","year":"2011","journal-title":"Congest Heart Fail."},{"key":"B21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijcard.2007.06.005","article-title":"Predictive values of the electrocardiogram in diagnosing pulmonary hypertension","volume":"127","author":"Al-Naamani","year":"2008","journal-title":"Int J Cardiol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.693414\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T22:12:08Z","timestamp":1673734328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.693414\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,11]]},"references-count":21,"alternative-id":["10.3389\/fcvm.2021.693414"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.693414","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2021,11,11]]},"article-number":"693414"}}